Revive Therapeutics Ltd.
RVV
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.92% | 79.99% | -32.67% | 54.52% | 20.79% |
| Depreciation & Amortization | -100.00% | -100.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -64.16% | 52.21% | -35.45% | -5.00% | -48.97% |
| Operating Income | 64.16% | -52.21% | 35.45% | 5.00% | 48.97% |
| Income Before Tax | 54.01% | -18.96% | -112.84% | 3.40% | 49.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.01% | -18.96% | -112.84% | 3.40% | 49.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.01% | -18.96% | -112.84% | 3.40% | 49.59% |
| EBIT | 64.16% | -52.21% | 35.45% | 5.00% | 48.97% |
| EBITDA | 64.16% | -52.27% | 35.49% | 4.99% | 48.97% |
| EPS Basic | 62.50% | 0.00% | -60.71% | 16.28% | 54.29% |
| Normalized Basic EPS | 50.00% | 0.00% | 40.00% | 18.52% | 54.55% |
| EPS Diluted | 62.50% | 0.00% | -60.71% | 16.28% | 54.29% |
| Normalized Diluted EPS | 50.00% | 0.00% | 40.00% | 18.52% | 54.55% |
| Average Basic Shares Outstanding | 16.98% | 17.03% | 30.64% | 17.24% | 10.14% |
| Average Diluted Shares Outstanding | 16.98% | 17.03% | 30.64% | 17.24% | 10.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |